The BIFSORB Pilot Study II
- Conditions
- Coronary Artery Disease
- Interventions
- Device: Magmaris
- Registration Number
- NCT03027856
- Lead Sponsor
- Aarhus University Hospital Skejby
- Brief Summary
The purpose of this study is to investigate the feasibility and safety of the Magmaris BRS for treatment of coronary bifurcation lesions.
- Detailed Description
Bioresorbable stents are promising in treatment of coronary artery disease. The concept of bifurcation treatment using BRS is particular appealing as struts covering the side branch ostium may resorb over time.
The aim of this study is to investigate the feasibility and safety of the Magmaris BRS for treatment of coronary bifurcation lesions.
Hypothesis: treatment of coronary bifurcation lesions using the Magmaris BRS is safe and feasible.
Methods:
The study is a proof-of-concept, prospective, single arm study with inclusion of 20 patients. Planned 1-and 12-month follow-up by optical coherence tomography (OCT) and follow-up for clinical endpoints until 5 years.
Written informed consent is required before the procedure is performed. Eligible patients with a bifurcation lesion are treated by the provisional technique with mandatory jailing of the side branch and provisional opening of side branch ostium by the mini-kiss technique in case of severe pinching or TIMI-flow less than III. Proximal post-dilatation is mandatory. No dilatation beyond the expansion limits of the stent.
At baseline, the target lesion is assessed by OCT before, during and after implantation of the Magmaris BRS. OCT assessment is performed again at 1- and 12-month follow-up, or before if the patient is readmitted with a possible target lesion failure.
The operator is not blinded to the OCT images as pre-PCI images should be used for sizing and positioning of the stent, and procedural OCT images are used to optimize stent implantation before performing final OCT.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Stable angina pectoris
- Stabilized non-ST elevation myocardial infarction
- Silent angina pectoris
- Age > 18 years
- De novo coronary bifurcation lesion at LAD/diagonal, CX/obtuse marginal or RCA-PDA/posterolateral branch
- All Medina classes except Medina x.x.1.
- Diameter of side branch ≥ 2.5 mm
- Side branch diameter stenosis less than 50%
- Signed informed consent
- ST-elevation infarction within 48 hours
- Expected survival < 1 year
- Severe heart failure (NYHA≥III)
- S-creatinine > 120 µmol/L or GFR < 0.45 mL/min per 1.73 m2
- Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine or sirolimus
- Unable to cover main vessel lesion with one stent
- Severe tortuosity
- Severe calcification
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Magmaris Magmaris Implantation of sirolimus eluting bioresorbable magnesium stent
- Primary Outcome Measures
Name Time Method Index of adverse vessel wall features by OCT 1 month Index based on: side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death 1 month Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
- Secondary Outcome Measures
Name Time Method Angiographic endpoint: Ostial side branch late loss 1 month Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting Baseline Angiographic endpoint: Proximal main vessel late loss 1 month Angiographic endpoint: Ostial side branch acute gain after main vessel stenting Baseline Optical coherence tomography endpoint: Acquired malapposition 1 month Optical coherence tomography endpoint: Mean neointimal thickness 1 month Optical coherence tomography endpoint: Extra stent lumen (including evaginations) Baseline and 1 month Optical coherence tomography endpoint: Late stent recoil 1 month Optical coherence tomography endpoint: Ostial strut loss Baseline and 1 month Angiographic endpoint: Proximal main vessel area stenosis Baseline and 1 month Procedural endpoint: Fluoroscopy time Intraoperative Optical coherence tomography endpoint: Persistent malapposition 1 month Optical coherence tomography endpoint: Coverage of jailing struts 1 month Optical coherence tomography endpoint: Stent strut coverage 1 month Optical coherence tomography endpoint: Minimum stent expansion area % Baseline and 1 month Optical coherence tomography endpoint: Healing above lipid plaque 1 month Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting Baseline Optical coherence tomography endpoint: Stent fracture Baseline and 1 month Optical coherence tomography endpoint: Minimal stent area in segmental analysis Baseline and 1 month Optical coherence tomography endpoint: Late recoil 1 month Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation
Procedural endpoint: Contrast use in mL Intraoperative Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death 60 months Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Optical coherence tomography endpoint: Acute malapposition Baseline Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts Baseline and 1 month Optical coherence tomography endpoint: Minimal luminal area in segmental analysis Baseline and 1 month Optical coherence tomography endpoint: Healing above calcified plaque 1 month Optical coherence tomography endpoint: Acute thrombus on struts Baseline Optical coherence tomography endpoint: Acute expansion Baseline Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation \< 30% of reference area, 4) stenosed segments (\>50% area stenosis) with no dissections after predilatation
Angiographic endpoint: Ostial distal main vessel area stenosis Baseline and 1 month Procedural endpoint: Procedure time Intraoperative Optical coherence tomography endpoint: Segmental area stenosis Baseline and 1 month Optical coherence tomography endpoint: Late thrombus on struts 1 month Angiographic endpoint: Ostial side branch area stenosis Baseline and 1 month Angiographic endpoint: Ostial distal main vessel late loss 1 month Angiographic endpoint: Minimal luminal area of all segments Baseline and 1 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Aarhus University Hospital
🇩🇰Aarhus N, Denmark